Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Cancer ; 105(6): 760-5, 2011 Sep 06.
Article in English | MEDLINE | ID: mdl-21811258

ABSTRACT

BACKGROUND: There is increased recognition that cancers of the upper GI tract comprise distinct epidemiological and molecular entities. Erlotinib has shown activity in patients with adenocarcinoma of the oesophagus/gastro-oesophageal junction (GEJ), but not in distal gastric cancer. mFOLFOX6 is one of several active regimens used to treat adenocarcinoma of the Eso/GEJ. This study evaluates the efficacy and safety of mFOLFOX6 and erlotinib in patients with metastatic or advanced Eso/GEJ cancers. METHODS: Patients with previously untreated advanced or metastatic Eso/GEJ adenocarcinoma are treated with oxaliplatin 85 mg m(-2), 5-FU 400 mg m(-2), LV 400 mg m(-2) on day 1, 5-FU 2400 mg m(-2) over 48 h and erlotinib 150 mg PO daily. Treatment was repeated every 14 days. The primary objective was response rate (RR), secondary objectives include toxicity, progression-free survival (PFS), overall survival (OS) and to correlate clinical outcome with expression patterns and molecular alterations in the epidermal growth factor receptor-dependent pathways. RESULTS: A total of 33 patients were treated and evaluable: there were two complete responses, 15 partial responses for an objective RR of 51.5% (95% CI, 34.5-68.6%). Median PFS was 5.5 months (95% CI, 3.1-7.5 months) and median OS was 11.0 months (95% CI, 8.0-17.4 months). The most common grade 3-4 toxicities were: diarrhoea (24%), nausea/vomiting (11%), skin rash (8%) and peripheral neuropathy (8%). The frequency of alterations was KRAS mutations (8%), EGFR mutations (0%) and HER2 amplification (19%). CONCLUSION: In patients with Eso/GEJ adenocarcinoma, mFOLFOX6 and erlotinib is active, has an acceptable toxicity profile and FOLFOX ± erlotinib could be considered for further development.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Esophageal Neoplasms/drug therapy , Esophagogastric Junction , Protein Kinase Inhibitors/administration & dosage , Quinazolines/administration & dosage , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Biomarkers, Tumor/analysis , Disease-Free Survival , Erlotinib Hydrochloride , Esophageal Neoplasms/pathology , Esophagogastric Junction/pathology , Female , Fluorouracil/adverse effects , Fluorouracil/therapeutic use , Humans , Leucovorin/adverse effects , Leucovorin/therapeutic use , Male , Middle Aged , Neoplasm Metastasis , Organoplatinum Compounds/adverse effects , Organoplatinum Compounds/therapeutic use
2.
Biorheology ; 31(1): 69-76, 1994.
Article in English | MEDLINE | ID: mdl-8173045

ABSTRACT

Exposure of human erythrocytes to subhemolytic shear stress is known to cause lipid loss and ion fluxes across the red cell membrane and to result in decreased filterability of suspensions of these cells. Damage to the lipid bilayer of traumatized erythrocytes has been examined by fluorescence anisotropy using the probe 1,6-diphenylhexatriene. Because literature methods for the introduction of the probe damaged the cells, a gentler method was developed using liposomes. Significant disruption of the lipid bilayer following subhemolytic trauma was detected by a decreased anisotropy of the membrane-bound fluorescent probe after stress.


Subject(s)
Erythrocyte Deformability/physiology , Erythrocyte Membrane/physiology , Adult , Diphenylhexatriene/administration & dosage , Erythrocytes/cytology , Female , Fluorescence Polarization/methods , Humans , Lipids/blood , Liposomes , Male , Stress, Mechanical
3.
Nature ; 346(6279): 79-81, 1990 Jul 05.
Article in English | MEDLINE | ID: mdl-2195353

ABSTRACT

Temperature is an important environmental factor affecting all organisms, and there is ample evidence from comparative physiology that species and even conspecific populations can adapt genetically to different temperature regimes. But the effect of these adaptations on fitness and the rapidity of their evolution is unknown, as is the extent to which they depend on pre-existing genetic variation rather than new mutations. We have begun a study of the evolutionary adaptation of Escherichia coli to different temperature regimes, taking advantage of the large population sizes and short generation times in experiments on this bacterial species. We report significant improvement in temperature-specific fitness of lines maintained at 42 degrees C for 200 generations (about one month). These changes in fitness are due to selection on de novo mutations and show that some biological systems can evolve rapidly in response to changes in environmental factors such as temperature.


Subject(s)
Biological Evolution , Escherichia coli/genetics , Selection, Genetic , Environment , Hot Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...